[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"direct-oral-anticoagulants-doacs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:direct-oral-anticoagulants-doacs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,75,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100635996","effect-of-apiban-therapy-on-avf-maturation-in-esrd-patients-100635996",false,"NCT07559942","Effect of Apiban Therapy on AVF Maturation in ESRD Patients","\"Effect of Perioperative and Short-Term Apixaban Therapy on Arteriovenous Fistula Maturation in Patients With End-Stage Renal Disease: A Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosis of ESRD (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m² or already on dialysis) with plans for hemodialysis.\n* Planned primary upper extremity AVF creation (radiocephalic, brachiocephalic, or brachiobasilic).\n* Suitable vessels on preoperative duplex ultrasound (artery ≥ 2 mm, vein ≥ 2.5 mm without tourniquet).\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known bleeding diathesis or hypercoagulable state.\n* Current therapeutic anticoagulation (any indication).\n* Current dual antiplatelet therapy.\n* History of intracranial hemorrhage.\n* Known allergy or hypersensitivity to apixaban.\n* Inability to comply with study protocol or follow-up.","ALL","18 Years",{"count":19,"type":20},190,"ESTIMATED","INTERVENTIONAL",[23],"NA","End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis \\[1\\]. AVFs offer superior longevity, fewer infectious complications, and lower mortality rates compared to central venous catheters or synthetic grafts \\[2\\]. However, a significant limitation to their widespread success is the high rate of early failure, primarily due to failure to mature (FTM). FTM occurs in 20-40% of AVFs, rendering them unusable for dialysis \\[3\\].\n\nApixaban, a direct factor Xa inhibitor, offers a potential advantage by providing sustained anticoagulation throughout the critical maturation period \\[7\\]. Its predictable pharmacokinetics, oral administration, and favorable safety profile make it an attractive agent for short-term use in this setting \\[8\\]. By reducing microthrombotic events during the first 4-6 weeks following AVF creation, apixaban could potentially improve maturation rates. However, this potential benefit must be weighed against the increased risk of bleeding, hematoma formation, and wound complications that could negatively impact fistula maturation \\[9\\].",[26,27,28,29],"Endstage Renal Disease","Direct Oral Anticoagulants (DOACs)","Arteriovenous Fistula","Arteriovenous Fistula Occlusion",[31,32,33,34],"arteriovenous fistula","maturation","anticoagulation","direct oral anticoagulants","RECRUITING","2026-05-02",{"date":38,"type":39},"2026-05-07","ACTUAL",{"date":41,"type":39},"2026-01-01",{"date":43,"type":20},"2026-08-31",{"name":45,"class":46},"Combined military hospital lahore","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100632992","oral-biopsy-bleeding-in-patients-on-direct-oral-anticoagulants-doacs-100632992","NCT07520890","Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)","Bleeding Outcomes Following Oral Soft Tissue Biopsy in Patients Receiving Direct Oral Anticoagulants","DOACS_BX","Inclusion Criteria:\n\n* capacity to understand and sign informed consent;\n* documented indication for oral soft tissue biopsy\n\nExclusion Criteria:\n\n* inability to provide consent;\n* congenital or acquired coagulopathy (including haemophilia, von Willebrand disease, thrombocytopenia, or hepatic cirrhosis);\n* active antiplatelet therapy other than low-dose aspirin",true,{"count":58,"type":20},100,"OBSERVATIONAL","Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited. This prospective case-control study compared intraoperative, perioperative, and postoperative bleeding in 50 patients on uninterrupted DOAC therapy versus 50 anticoagulant-naive controls undergoing standardized oral soft tissue biopsy with suturing. All bleeding events were managed with local haemostatic measures. The study aims to determine whether DOAC continuation is safe for this procedure.",[27,62],"Oral Surgical Procedures",[34,64,65],"post-operative bleeding","oral surgery","2026-04-02",{"date":68,"type":39},"2026-04-09",{"date":70,"type":39},"2026-04-01",{"date":72,"type":20},"2026-12-31",{"name":74,"class":46},"University of Pisa",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":85,"conditions":86,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100616764","hip-fracture-surgery-timing-and-blood-transfusion-risk-in-patients-on-doacs-100616764","NCT07309848","Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs","Blood Transfusion Risk After Early vs. Delayed Surgery in Hip Fracture Patients on Direct Oral Anticoagulants: A Natural Experiment","OPTIMIZEDOAC","Inclusion Criteria:\n\n* Isolated hip fracture classified as AO\u002FOTA 31A or 31B requiring surgical intervention.\n* Current DOAC use with the last dose taken ≤24 hours before emergency department (ED) presentation\n\nExclusion Criteria:\n\n* Pathologic or periprosthetic hip fractures.\n* Fracture sustained \\>24 hours before ED presentation.\n* Inter-hospital transfer.\n* Hematologic disorders (e.g., thalassemia, sickle cell disease, aplastic anemia, myelodysplastic syndromes, leukemia).\n* Use of a non-EMA-approved DOAC (e.g., betrixaban).",{"count":84,"type":20},374,"This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting longer can also increase risks such as complications and longer hospital stays. The purpose of this study is to find out whether operating within 24 hours is as safe as delaying surgery beyond 24 hours. Specifically, the investigators want to know if early surgery does not lead to a higher need for blood transfusions compared to delayed surgery.",[87,88,89,90,91,92,93,94,27],"Blood Transfusion","Hip Fracture Surgeries","Geriatric","Bleeding Complications","Bleeding as Surgical Complication (Treatment)","Bleeding","Blood Transfusions","Blood Transfusion Complication",[96,97,98,99,100,101,102,103,104,105],"natural experiment","doac","direct oral anticoagulant","hip fracture","geriatric","surgery","bleeding","blood transfusion","early","delayed","2025-12-15",{"date":108,"type":39},"2025-12-30",{"date":110,"type":39},"2025-11-01",{"date":112,"type":20},"2027-12-31",{"name":114,"class":46},"St. Antonius Hospital",7,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":126,"studyType":59,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":47},"100587499","observatoire-international-des-patients-antiphospholipides-traits-par-anticoagulants-oraux-directs-100587499","NCT06929182","OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs","OBServaToIre National Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs","OBSTINATE 2","Inclusion Criteria:\n\n* Person having received complete information on the organization of the research and not having opposed the use of this data\n* Male or female aged 18 and over;\n* Carrier of a thrombotic APS according to the Sydney classification criteria, regardless of the length of time in the disease\n* Having received a direct oral anticoagulant (DOAC) treatment which is currently discontinued.\n* Or currently treated with DOAC\n\nExclusion Criteria:\n\n* Incomplete Sydney classification criteria\n* Presence of a triple antiphospholipid positivity\n* History of arterial thrombosis\n* Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code:\n\n  * Pregnant, parturient or nursing mother\n  * Minor person (not emancipated)\n  * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n  * Person of full age unable to express consent\n* Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1 of the French Public Health Code.\n* Signature of the research participation opposition form",{"count":125,"type":20},500,"5 Years","This registry will make it possible to collect large-scale data on SAPL patients, particularly those treated with DOACs, in order to better assess the frequency of thrombotic and hemorrhagic events in this population of \"non-high-risk\" thrombotic SAPL patients treated with DOACs. The results will help refine treatment recommendations and could form the basis of future clinical trials.\n\nIn this study, there will be no modification of the usual care and no additional follow-up. Follow-up will be carried out during the patient's usual visits in the context of his or her pathology, the frequency of which will be left to the discretion of the usual physician. No additional consultations\u002Fhospitalizations\u002Fexaminations will be carried out as part of the study. Data normally recorded in the medical record will be collected over a 5-year period, in line with standard patient follow-up.",[129,27,130,131],"Antiphospholipid Syndrome (APS)","Thrombotic and Bleeding Events","Safety",[133,134,135,136,137],"safety of DOACs",""non-high risk" APS patients","Observatory","Phase IV","International","NOT_YET_RECRUITING","2025-04-16",{"date":141,"type":39},"2025-04-20",{"date":143,"type":20},"2025-07-01",{"date":145,"type":20},"2035-07-01",{"name":147,"class":46},"Central Hospital, Nancy, France"]